|
Outcomes after major cancer surgery: Can we predict them using parsimonious models? |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Castle Biosciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; Johnson & Johnson; Pfizer |
Speakers' Bureau - Janssen Oncology |
Research Funding - Novartis |
|
|
Consulting or Advisory Role - Celgene; Merck |